By Hannah Rabinowitz, Steve Contorno, Alicia Wallace, NCS
(NCS) — Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical marijuana as a less dangerous drug, altering a coverage that has for many years made the drug’s potential medicinal advantages harder to analysis.
The order from Blanche doesn’t make leisure use authorized below federal legislation. Instead, it strikes licensed medical marijuana from Schedule I — that are probably the most restricted medicine such as heroin and ecstasy — to Schedule III, the identical class as some prescription medicines like ketamine and Tylenol with codeine.
It additionally offers a tax break to licensed medical marijuana sellers and eases some restrictions on researching its results.
“These actions will enable more targeted, rigorous research into marijuana’s safety and efficacy, expanding patients’ access to treatments and empowering doctors to make better-informed healthcare decisions,” Blanche wrote in a social media put up on X.
The Drug Enforcement Administration may even maintain administrative hearings earlier than a choose in June on reclassifying marijuana extra broadly, Blanche mentioned.
A full rescheduling of marijuana to Schedule III may have important implications for a giant swath of state-licensed companies that develop, make and promote hashish for leisure use as properly as others not topic to Thursday’s order.
For now, nevertheless, the business is cut up into two tiers, and different companies (particularly operators that maintain each an adult-use and medical license) stay in a state of limbo.
“They’ve bifurcated one plant into two different schedules, which is very odd to me,” Colorado-based lawyer Rachel Gillette, a Holland & Hart associate who has practiced hashish legislation since 2010, instructed NCS in an interview.
Gillette known as Thursday’s order a step in the precise route, however acknowledged that it opens up extra questions than solutions.
“It certainly is going to cause a lot of potential confusion and complications if it remains in this status quo and the hearing come June doesn’t lead to broader rescheduling,” she mentioned.
A slow-moving effort
The White House celebrated the Justice Department reclassifying state-licensed marijuana as “a welcome step to increase critical research into possible medical applications of cannabis.”
“The Trump administration continues to implement a Gold Standard Science-based approach to shape health policymaking and deliver for American veterans and patients,” White House spokesman Kush Desai mentioned in a assertion to NCS.
The effort to downgrade marijuana’s classification has been mentioned and tried by a number of administrations, however none have been profitable in finalizing a rule. Former President Joe Biden initiated a new attempt within the final yr of his presidency, but it surely wasn’t accomplished earlier than he left workplace.
Critics blamed reluctancy from then-DEA Administrator Anne Milgram for slow-walking the method. The rule had been equally scheduled for administrative hearings earlier than the tip of Biden’s time period however was placed on pause indefinitely by the DEA’s high choose.
In an executive order final December, President Donald Trump ordered the Justice Department to expedite the method and push by means of Biden’s proposed rule change.
But there was little public motion within the continuing months, and advocates of eased laws grew annoyed.
Trump himself appeared to precise frustration concerning the delay over the weekend, telling podcaster Joe Rogan, a supporter of rescheduling marijuana, at an Oval Office occasion that “they’re slow-walking me.”
Sources instructed NCS that within the White House and Justice Department have additionally confronted rising strain from the hashish business to get the scheduling change over the road.
As a plan to maneuver ahead was being finalized, some within the division hoped to publicize its efforts on April 20 — a day of celebration for marijuana fanatics — however have been instructed that it will be unseemly, two sources acquainted with the discussions mentioned.
Now, the reinvigorated effort is prone to face swift authorized challenges from critics who say that the downgrade may encourage leisure use of a dangerous drug.
Smart Approaches to Marijuana, an advocacy group that opposes marijuana legalization, mentioned in a assertion that it is going to be “taking legal action immediately” in opposition to the order.
“The only thing today’s decision advances are the interests of an addiction-for-profit industry—and if the president isn’t going to use the Food and Drug Administration as the law requires, why doesn’t he simply abolish it,” the assertion mentioned.
Still, loosening restrictions round marijuana is broadly well-liked. A 2024 Pew Research Center survey discovered almost six in 10 Americans assist the legalization of leisure hashish.
Twenty-four states, two territories and Washington, DC, have legalized hashish for grownup leisure use, and 40 states, three territories and DC permit medical use of hashish merchandise, in accordance with information from the National Conference of State Legislatures. Since the primary adult-use hashish sale passed off in 2014 in Colorado, hashish has blossomed into a multibillion-dollar industry that has attracted the eye of multinational companies throughout sectors such as alcohol, agriculture, pharmaceutical and tobacco.
It stays unclear how Wednesday’s rescheduling directive may have an effect on state-legal hashish companies which have each leisure and medical licenses.
Kim Rivers, the CEO of the marijuana firm Trulieve, thanked each Trump and Blanche for “delivering” on their promise to reclassify marijuana.
“The dual approach of utilizing the treaty pathway and the rulemaking process ensures rescheduling medical marijuana happens quickly and completely and is an unequivocal statement of the President’s commitment to make good on his campaign promise,” she mentioned.
Economic impacts
The federal authorities acknowledging marijuana’s medical worth shouldn’t be solely symbolically highly effective but in addition may serve as a permissive sign to state-level lawmakers at the moment weighing hashish laws, mentioned Brian Vicente, a founding associate of Vicente LLP, a Denver-based hashish legislation agency.
A rescheduling would carry sensible implications as properly, he mentioned, noting one of the vital important being that hashish companies would possibly not be topic to Internal Revenue Code Section 280E, an early Eighties tax provision that prohibits companies engaged within the “trafficking” of Schedule I or II substances from deducting atypical enterprise bills or claiming tax credit.
“We’re talking about billions of dollars in new economic activity, tens of thousands of new jobs or just really a wind in the sail for this industry that’s really paid a very heavy tax burden for years,” Vicente mentioned. “That would be life-changing for many, many state-legal cannabis businesses.”
Since 2018, hashish companies have paid an estimated $15 billion in extra 280E-related taxes, in accordance with an evaluation launched earlier this month by Whitney Economics. Subject to 280E, some hashish companies have an efficient tax price of 70% or extra, in accordance with the Portland, Oregon-based hashish and hemp consulting and financial analysis agency.
“By removing this tax burden, you’re going to have a substantial positive impact on these businesses, their ability to hire, their ability to pay higher wages, their profitability,” Vicente mentioned. “In somewhat of a challenging economy, this could be a real win for those states that have these businesses.”
The Internal Revenue Service would probably need to problem steering on shifting marijuana to Schedule III, Vicente mentioned.
Another real-world implication of rescheduling can be the acceleration of medical analysis on hashish, he mentioned.
“For years in Colorado and across the country, I’ve talked to universities and hospitals that want to allow research, but they’re afraid of federal illegality and losing federal funds,” he mentioned. “While this would not change the legality of cannabis, it would move it to Schedule III, which would help fast-track research and certainly reduce some of the stigma attached to this medicine.”
What shouldn’t be anticipated to vary, he mentioned, would be the state-level legal guidelines and laws involving leisure and medical hashish.
Rescheduling marijuana is not going to remedy the longstanding federal-state battle: The cultivation, manufacture, sale and possession of marijuana for leisure use would stay unlawful below federal legislation and doubtlessly topic to enforcement and prosecution.
States’ authorized medical marijuana companies do at the moment have some federal protections in place through appropriations laws that restricts the Justice Department from interfering in these applications.
This story has been up to date with further data.
The-NCS-Wire
™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
NCS’s Kit Maher contributed to this report.